Identification of tumors which exhibit high expression of COL10A1 and its associated genes may reveal the presence of more aggressive pathological microenvironments with heightened EMT and metastatic capacity, potentially enabling more effective risk assessment and treatment of patients with breast and pancreatic cancer. This evidence concerns the gene COL10A1 and familial pancreatic carcinoma.